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OBJECTIVE— This study was performed to 1) determine the prevalence of celiac disease in
Danish children with type 1 diabetes and 2) estimate the clinical effects of a gluten-free diet
(GFD) in patients with diabetes and celiac disease.
RESEARCH DESIGN AND METHODS— In a region comprising 24% of the Danish
population, all patients16 years old with type 1 diabetes were identified and 269 (89%) were
included in the study. The diagnosis of celiac disease was suspected in patients with endomysium
and tissue transglutaminase antibodies in serum and confirmed by intestinal biopsy. Patients
with celiac disease were followed for 2 years while consuming a GFD.
RESULTS— In 28 of 33 patients with celiac antibodies, an intestinal biopsy showed villous
atrophy. In 5 patients, celiac disease had been diagnosed previously, giving an overall prevalence
of 12.3% (95% CI 8.6–16.9). Patients with celiac disease had a lower SD score (SDS) for height
(P 0.001) and weight (P 0.002) than patients without celiac disease and were significantly
younger at diabetes onset (P 0.041). A GFD was obtained in 31 of 33 patients. After 2 years of
follow-up, there was an increase in weight SDS (P  0.006) and in children 14 years old an
increase in height SDS (P 0.036). An increase in hemoglobin (P 0.002) and serum ferritin
(P  0.020) was found, whereas HbA1c remained unchanged (P  0.311) during follow-up.
CONCLUSIONS— This population-based study showed the highest reported prevalence of
celiac disease in type 1 diabetes in Europe. Patients with celiac disease showed clinical improve-
ments with a GFD. We recommend screening for celiac disease in all children with type 1
diabetes.
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I t is well established that celiac diseaseis overrepresented in different autoim-mune diseases, notably type 1 diabetes.
Also celiac disease itself has features char-
acteristic of an autoimmune disease. In
numerous studies from European coun-
tries over the last 30 years, the prevalence
of celiac disease in children with type 1
diabetes has been reported to be 2–8%
(1). Surprisingly, no strictly population-
based studies have been published, as
judged from the presented material, even
though two large studies from Italy (2)
and Germany (3) comprise a considerable
percentage of the national diabetic popu-
lation.
In Denmark, the prevalence of recog-
nized cases of celiac disease in the general
population is very low compared with the
prevalence in other neighboring countries
(4,5). On the other hand, a high incidence
of childhood type 1 diabetes has been
documented (6). Therefore, it appeared
to be particularly interesting to determine
the prevalence of celiac disease in Danish
type 1 diabetic children. In a preliminary
study, we found a prevalence of celiac dis-
ease of 10% in Danish type 1 diabetic chil-
dren (7). In the present study, we
extended this investigation to a larger
population. The study was performed in a
strictly population-based design, includ-
ing all type 1 diabetic children from a re-
gion representing one-fourth of the
Danish population.
Despite the high prevalence of celiac
disease in type 1 diabetes, the issue of rou-
tine screening of all type 1 diabetic chil-
dren has been much debated (8). Many
diabetic patients in whom celiac disease
has been diagnosed through screening are
asymptomatic or have nonspecific symp-
toms of celiac disease (1). The benefits of
a gluten-free diet (GFD) in those patients,
both in the short- and long-term, are not
well established. In a few previous studies
of patients with both type 1 diabetes and
celiac disease, the effect of a GFD on
symptoms, growth, and metabolic con-
trol has been investigated, but with incon-
sistent results (9 –12). In the present
study, the clinical course in diabetic chil-
dren with celiac disease was evaluated
during a 2-year follow-up period when
they consumed a GFD.
RESEARCH DESIGN AND
METHODS— In Denmark, the treat-
ment of all children with type 1 diabetes is
restricted to the pediatric departments
within the hospital-based health system.
The present study was performed in the
region of southern Denmark consisting of
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four counties, each with one pediatric de-
partment. All children 16 years old
from the pediatric departments in the four
counties were included. In the county of
Funen, patient identification was per-
formed in 1997 as previously reported
(7). In the remaining three counties, the
children were investigated through
2002–2003.
At study entry, all patients were inter-
viewed by the doctor about symptoms
compatible with celiac disease, and a
symptom questionnaire was filled out.
Height and weight were registered. Blood
samples were obtained and analyzed for
specific antibodies. Serum anti-gliadin
antibodies (IgG and IgA AGAs) were mea-
sured by enzyme-linked immunosorbent
assay (13); cutoff value was 15 arbitrary
units (AU). Serum anti-tissue transglu-
taminase antibodies (IgA tTGAs) were
measured by enzyme-linked immunosor-
bent assay (INOVA Diagnostics); cutoff
value was 20 AU. Antibodies against en-
domysium (IgA EMA) in serum were
measured by indirect immunofluores-
cence using monkey esophagus tissue
(INOVA Diagnostics) as substrate. The
fluorescence intensity was reported semi-
quantitatively (0, 1, 2, and 3). In
patients from the county of Funen, anti-
body analyses were initially performed at
another laboratory (7). Frozen sera from
those patients were reanalyzed by the
above mentioned methods, and identical
results were obtained.
In patients only positive for IgG AGA,
total serum IgA was determined to ex-
clude IgA deficiency. In patients with pos-
itive IgA AGA, EMA, and/or tTGA
antibodies, an intestinal biopsy was per-
formed. Endoscopic duodenal biopsy
samples were taken and examined histo-
logically by a gastroenterological pathol-
ogist. In patients with partial or total
villous atrophy, a GFD was instituted af-
ter careful instructions by a dietitian. Sub-
sequently, patients were seen by the
doctor in the outpatient clinic every 3rd
month for a minimum period of 2 years.
At each visit, celiac disease–related symp-
toms and growth parameters were sche-
matically registered. Blood samples were
taken, and measurements of celiac anti-
bodies and other hematological parame-
ters (hemoglobin, mean corpuscular
volume, serum ferritin, folate, cobalamin,
glycosylated hemoglobin, ionized cal-
cium, and alanine aminotransferase) were
performed using routine analytical meth-
ods. After 2 years follow-up with the pa-
tient consuming a GFD, another intestinal
biopsy was offered to all patients with ce-
liac disease.
In patients with positive celiac anti-
bodies, HLA typing was performed. HLA-
DQB1* and -DQA1* typing was done by
PCR amplification with sequence-specific
primers. DRB1* alleles were detected by
PCR amplification with sequence-specific
oligonucleotides using the One Lambda
Lab Type rSSO typing system for HLA
typing.
All patients and their parents gave in-
formed written consent, and the study
was approved by the regional ethical com-
mittees. The study was performed in ac-
cordance with Helsinki Declaration II.
Statistics
The statistical package Intercooled
STATA 7 was used for the statistical anal-
yses. For comparisons between groups,
the Mann-Whitney rank-sum test and
Fishers exact test were used; 95% CIs for
proportions were calculated by use of the
binomial distribution. The follow-up data
were analyzed using the Wilcoxon
signed-rank test for paired observations.
P values 0.05 were considered statisti-
cally significant.
RESULTS— A total of 303 patients
with type 1 diabetes were identified in the
four counties, and 269 (89%) accepted to
participate. The included patients had a
median age of 10.9 years (range 1.5–16.0)
and a median duration of diabetes of 3.1
years (range 0.1–14.5). Five of them had a
previous diagnosis of celiac disease and
were consuming a GFD.
IgA AGAs were found in 11 and IgG
AGAs in 28 of the patients investigated.
All patients with IgA AGAs also had EMAs
and tTGAs. Sixteen patients with low ti-
ters (30 AU) of IgG AGA had neither
EMA nor tTGA. In those patients IgA de-
ficiency was excluded, and they were not
further investigated. EMAs and tTGAs
were found in 33 of 269 patients, and
there was an absolute correlation between
the presence of these antibodies. In all but
one patient, an intestinal biopsy was ob-
tained. In 28 of 32 patients, the biopsy
showed partial or total crypthyperplastic
villous atrophy. In four patients, the bi-
opsy showed normal intestinal mucosa;
although in one of them, increased lym-
phocyte infiltration in lamina propria was
noted. Thus, including the 5 patients pre-
viously diagnosed with celiac disease, a
total of 33 of 269 patients (17 female and
16 male) had celiac disease, correspond-
ing to a prevalence of 12.3% (95% CI
8.6–16.9).
Table 1 presents clinical characteris-
tics of diabetic subjects with celiac disease
compared with diabetic subjects without
celiac disease. Patients with celiac disease
had a significantly lower age at diabetes
onset (P  0.042), whereas there was no
difference comparing age and sex in the
two groups. The patients with celiac dis-
ease had a significantly lower height SD
score (SDS) (P  0.001) and weight SDS
(P  0.002). In the interview, they re-
ported symptoms of celiac disease signif-
icantly more often (P  0.001) than
patients without celiac disease. Table 2
presents the prevalence of celiac disease–
related symptoms in both groups. In four
patients with celiac disease, the symp-
toms were first recognized in retrospect
after a GFD was instituted. Only 5 of 33
(15%) patients with celiac disease had no
clinical signs of the disease.
HLA genotyping, performed only in
the patients with celiac disease, showed
the HLA DQ2 genotype in 28 of 33 (85%)
of the patients, HLA DQ8 in 12 of 33
(36%), and both DQ2 and DQ8 in 8 of 33
(24%). A single patient had neither the
HLA DQ2 nor the DQ8 genotype. The
four patients with celiac antibodies but
normal biopsy findings all had the HLA
DQ2 and/or DQ8 genotype.
Table 1—Clinical characteristics of diabetic patients with celiac disease compared with dia-
betic patients without celiac disease
Characteristics
Diabetic patients with
celiac disease
Diabetic patients without
celiac disease P value
n 33 236
Sex (female/male) 17/16 110/126 0.710
Age (years) 9.4 (2.0–16.0) 11.1 (1.5–15.9) 0.096
Age at diabetes onset (years) 5.8 (0.7–12.7) 6.6 (0.6–14.9) 0.042
Height SDS 0.65 (3.5 to 2.1) 0.4 (3.2 to 2.8) 0.001
Weight SDS 0.1 (1.4 to 1.4) 0.5 (1.9 to 5.0) 0.002
Prevalence of symptoms (%) 84.8 25.4 0.001
*Data are median (range) unless otherwise indicated.
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A GFD was initiated in 31 of 33 pa-
tients with celiac disease, whereas 2
asymptomatic patients refused to start the
diet. In 24 of 31 patients, the celiac anti-
bodies disappeared, confirming the diag-
nosis of celiac disease according to the
revised European Society for Paediatric
Gastroenterology Hepatology and Nutri-
tion (ESPGHAN) criteria (14). In seven
patients with variable compliance to the
GFD, the celiac antibodies declined dur-
ing follow-up but never became negative
(Fig. 1). In many patients, the decrease in
celiac antibody titers was slow, and the
antibodies became negative after 1–2
years on a strict diet. Almost all of the
symptomatic patients experienced relief
of symptoms while consuming the GFD
(Table 2), whereas three asymptomatic
patients experienced no changes. Table 3
demonstrates the development of differ-
ent clinical and biochemical parameters at
6, 12, 18, and 24 months of follow-up
compared with baseline. After 2 years of
follow-up, there was a significant increase
in weight SDS (P  0.002), whereas the
increase in height SDS (P  0.073) did
not reach significance. However, when
patients who were 14 years old at the
onset of the study were excluded, there
was also a significant increase in height
SDS (P  0.036). There was a significant
increase in hemoglobin (P  0.001),
mean corpuscular volume (P  0.020),
and serum ferritin (P  0.012). A signif-
icant increase in serum folate was found
after 6, 12, and 18 months, but the in-
crease did not reach statistical signifi-
cance at 24 months (P  0.076). No
significant change in HbA1c (A1C) was
seen during the 2 years of follow-up. In 18
of 33 patients, a second intestinal biopsy
was performed after they consumed a
GFD for 2 years. In 14 patients, the intes-
tinal mucosa had normalized, whereas in
4 patients, who did not follow a strict diet,
the mucosa had only partially recovered.
CONCLUSIONS— In the present
study, we investigated a total of 269 chil-
dren16 years old, representing 89% of
all children with type 1 diabetes in this
age-group in an area representing 25%
of the Danish population. In this popula-
tion, we found a prevalence of celiac dis-
ease of 12.3% (95% CI 8.6–16.9). The
prevalence of celiac disease might be even
higher. A single patient who had no bi-
opsy sample taken still has very high ce-
liac antibody titers. Four patients with
celiac antibodies, all HLA DQ2 and/or
DQ8 positive, had normal biopsy findings
but may have latent celiac disease. A sin-
gle patient, who was antibody negative at
the primary screening, later developed
symptoms of celiac disease, and the diag-
nosis was confirmed by celiac antibodies
and intestinal biopsy. Finally, patients
with celiac disease might have been
missed because of false-negative serology
results (15). The high prevalence of celiac
disease among Danish diabetic patients is
surprising in view of the low prevalence of
recognized celiac disease in the general
population in Denmark (4). A similar
screening study in the general population
might possibly reveal a prevalence of ce-
liac disease of 1% as found in many
other European countries (16).
In previous studies, most of which are
from other European countries, the prev-
alence of celiac disease in type 1 diabetic
children has generally been lower than
that in the present study (1). Genetic and
environmental factors might account for
some of the regional differences. How-
ever, the higher celiac disease prevalence
in the present study might also be ex-
plained by differences in study condi-
tions: 1) this study was population-based,
whereas previous studies have been based
on outpatient clinics with no detailed re-
ports of demographic data; 2) we used
sensitive and specific celiac antibody tests
Figure 1—The development of tissue transglutaminase antibodies in children with type 1 diabetes
and celiac disease, measured 0, 6, 12, 18, and 24 months after starting a GFD. , patients
adherent to GFD;, patients not strictly adherent to GFD.
Table 2—Prevalence of celiac disease–related symptoms reported by the diabetic patients
before screening for celiac disease was performed and by patients with celiac disease after 2
years of consuming a GFD
Symptoms*
Patients without
celiac disease
Patients with
celiac disease
P
value
Patients consuming
a GFD
n 236 33
Abdominal pain 23 (9.7) 16 (48.5) 0.001 0†
Loose and/or frequent stools 15 (6.4) 7 (21.2) 0.010 2 (6.5)
Bloating 24 (10.2) 9 (27.2) 0.021 3 (9.7)
Constipation 2 (0.8) 3 (9.0) 0.014 0
Arthralgias 10 (4.2) 7 (21.2) 0.002 1 (3.2)
Tiredness 6 (2.5) 8 (24.2) 0.001 0
Frequent hypoglycemia 1 (0.4) 2 (6.0) 0.040 0
Aphthous ulcers 1 (0.4) 1 (3.0) 0.230 0
Tooth enamel defects 8 (3.4) 3 (9.0) 0.139 —
Hemoglobin 6.5 mmol/l — 4 (12.1) — 0
Serum ferritin 15 g/l — 9 (27.2) — 1 (3.2)
Thyroid antibodies 13 (5.5) 3 (9.0) 0.425 —
Dermatitis herpetiformis 0 1 (3.0) 0.122 —
Autoimmune hypothyroiditis 0 4 (12.1) 0.001 —
Data are n (%). *A few patients with celiac disease first reported symptoms in retrospect after experiencing
the relief with the GFD (three patients reported abdominal pain, a single patient reported abdominal pain,
diarrhea, and tiredness, and another patient reported arthralgias). †Some patients reported abdominal pain
at breach of the diet.
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(IgA EMAs and tTGAs) (17); 3) in contrast
with many other studies, all but one of the
celiac antibody-positive patients in the
present study did consent to intestinal bi-
opsy; and 4) we also included patients
with previously diagnosed celiac disease.
Our conclusion is that the much lower
prevalences of celiac disease in type 1 di-
abetes found in some European countries
might be underestimates of the true prev-
alence in the population.
In the present study, patients with ce-
liac disease had a significantly earlier on-
set of diabetes compared with diabetic
subjects without celiac disease (Table 1).
This observation is in agreement with
some (3,18,19) but not all (20–22) pre-
vious studies. In a recent Italian multi-
center study in which 4,322 young
patients with type 1 diabetes were inves-
tigated, a threefold higher risk for celiac
disease was found in children 4 years
old at the onset of diabetes than in those
9 years old (2). In Denmark, an increase
in the incidence of type 1 diabetes in chil-
dren5 years old has been observed dur-
ing recent years (6). If the association
between young age at diabetes onset and
the development of celiac disease is con-
sistent, an increase in the number of pa-
tients with both diseases might be
expected.
Most patients with celiac disease di-
agnosed through screening are described
as having subclinical celiac disease (23).
In the present study, only 5 of 33 (15%) of
diabetic subjects with celiac disease had
the diagnosis before our screening even
though the majority of the patients with
celiac disease reported symptoms of celiac
disease in their interview. Only 5 patients
with celiac disease presented with no
symptoms or biochemical signs of celiac
disease. This observation supports rec-
ommendations of screening for celiac dis-
ease in type 1 diabetic patients. Despite
an increased clinical awareness from the
physicians, celiac disease may remain
undiagnosed in many patients with type
1 diabetes if regular screening is not
performed.
Although a considerable number of
screening studies have been performed,
only a few studies described the effects of
a subsequent GFD in patients with type 1
diabetes and celiac disease. In the present
study 31 of 33 patients with both diseases
were followed while they consumed a
GFD for at least 2 years. During follow-
up, the symptomatic patients experienced
increased well-being. In a few patients
with variable compliance to the diet, mi-
nor symptoms remained (Table 2). The
majority of patients became celiac anti-
body negative after 3 to 24 months after
starting the GFD. At diagnosis of celiac
disease, we found that patients were
stunted in their growth, with both height
and weight SDSs being affected, com-
pared with diabetic patients without ce-
liac disease (Table 1). After 2 years of
consuming a GFD, patients with celiac
disease had a significant increase in
weight SDS. In patients 14 years old, a
significant increase in height SDS was also
seen, reflecting the potential for growth in
younger patients. In accordance with this
finding, some previous researchers have
reported an impairment of growth in pa-
tients with celiac disease and type 1 dia-
betes compared with diabetic control
subjects (3,9). In longitudinal studies of
diabetic patients consuming a GFD, Amin
et al. (9) found an increase in BMI SDS,
Saadah et al. (10) showed an increase in
weight-for-age z scores, and Sanchez-
Albisua et al. (12) found an increase in
height SDS in patients with good dietary
compliance. On the other hand, Rami et
al. (11) and Westman et al. (24) found no
improvement in neither BMI SDS or
height SDS on a GFD. However, most fol-
low-up studies have been small, and in-
terpretation of the results is difficult
because of variable dietary compliance in
the patients investigated.
In the present study, we evaluated he-
matological markers, often affected in pa-
tients with celiac disease. Iron deficiency
anemia is a frequent symptom in children
with celiac disease (23). In our patients,
we found a significant increase in hemo-
globin, mean corpuscular volume, and se-
rum ferritin after 2 years of consuming a
GFD. Acerini et al. (25) measured the
same parameters longitudinally in a small
group of seven diabetic patients consum-
ing a GFD but could not demonstrate any
significant changes. An important aspect
in patients with type 1 diabetes and celiac
disease is the metabolic control with a
GFD. In the present study, A1C was al-
most unchanged in patients consuming a
GFD. In a few studies, a decrease in A1C
was seen in diabetic subjects after a GFD
(9,12), whereas others could not demon-
strate any improvements (10,11,25,26).
However, A1C may not by itself reflect the
metabolic control in diabetic subjects
consuming a GFD. In the present study,
two patients experienced fewer episodes
of hypoglycemia after the start of the
GFD. Mohn et al. (27) also described fre-
Table 3—Development of different clinical parameters in patients with type 1 diabetes and celiac disease measured before and after 6, 12, 18,
and 24 months of starting a GFD
Duration of the GFD
n Baseline 6 months 12 months 18 months 24 months P value
Weight SDS 27 0.12 0.11 0.25* 0.30* 0.35* 0.002
Height SDS 27 0.46 0.37 0.31 0.24 0.26 0.073
A1C (%) 28 8.6 9.0 8.8 8.7 8.4 0.300
Hemoglobin (mmol/l) 25 7.6 8.4* 8.3* 8.4* 8.3* 0.001
Mean corpuscular volume (fl) 25 81.6 83.0 83.8 83.5 84.4* 0.020
Ferritin (g/l) 26 26.0 31.1 39.8* 44* 37.9* 0.012
Folate (nmol/l) 24 489 606* 637* 639* 581 0.076
Cobalamin (pmol/l) 25 387 416 415 395 379 0.872
Calcium (mmol/l) 23 1.24 1.26* 1.26* 1.26* 1.26* 0.044
ALAT (units/l) 26 24.9 27.2 21.0 19.7* 20.6 0.062
Data are means of the group. At 24 months follow-up, the corresponding P values are also presented. Only a few follow-up data were available from patients with
celiac disease diagnosed before this study. The increase in hemoglobin was not caused by the increase in hemoglobin seen in male puberty. Paired comparisons were
performed by Wilcoxon signed-ranked test. *Significant changes from baseline.
Hansen and Associates
DIABETES CARE, VOLUME 29, NUMBER 11, NOVEMBER 2006 2455
quent episodes of hypoglycemia in dia-
betic children with celiac disease with a
reduction in the hypoglycemic risk with a
GFD. Continuous blood glucose moni-
toring and careful registration of insulin
requirements before and after the start of
the GFD would give further valuable in-
formation about the metabolic control.
In summary, in a population-based
study of Danish children with type 1 dia-
betes, we found a high prevalence of ce-
liac disease. The occurrence of celiac
disease was associated with young age at
diabetes onset. Patients with celiac dis-
ease were stunted in their growth, and
many had unrecognized symptoms of ce-
liac disease. Longitudinal follow-up after
consumption of a GFD in this cohort of
patients demonstrated symptom relief
and improvements in growth parameters,
but no significant changes in metabolic
control. The data lend support to recom-
mendations of regular screening for celiac
disease in all children with type 1 diabetes.
Acknowledgments— This study received
support from The Danish Research Agency
and from the counties of Funen, Vejle, and
Southern Jutland.
References
1. Collin P, Kaukinen K, Valimaki M, Salmi
J: Endocrinological disorders and celiac
disease. Endocr Rev 23:464–483, 2002
2. Cerutti F, Bruno G, Chiarelli F, Lorini R,
Meschi F, Sacchetti C: Younger age at on-
set and sex predict celiac disease in chil-
dren and adolescents with type 1
diabetes: an Italian multicenter study. Di-
abetes Care 27:1294–1298, 2004
3. Kaspers S, Kordonouri O, Schober E, Gra-
bert M, Hauffa BP, Holl RW: Anthropom-
etry, metabolic control, and thyroid
autoimmunity in type 1 diabetes with ce-
liac disease: a multicenter survey. J Pediatr
145:790–795, 2004
4. Bode S, Gudmand-Hoyer E: Incidence
and prevalence of adult coeliac disease
within a defined geographic area in Den-
mark. Scand J Gastroenterol 31:694–699,
1996
5. Sjoberg K, Eriksson S: Regional differ-
ences in coeliac disease prevalence in
Scandinavia? Scand J Gastroenterol 34:41–
45, 1999
6. Svensson J, Carstensen B, Molbak A,
Christau B, Mortensen HB, Nerup J,
Borch-Johnsen K: Increased risk of child-
hood type 1 diabetes in children born af-
ter 1985. Diabetes Care 25:2197–2201,
2002
7. Hansen D, Bennedbaek FN, Hansen LK,
Hoier-Madsen M, Hegedu¨s L, Jacobsen
BB, Husby S: High prevalence of coeliac
disease in Danish children with type I di-
abetes mellitus. Acta Paediatr 90:1238–
1243, 2001
8. Freemark M, Levitsky LL: Screening for
celiac disease in children with type 1 dia-
betes: two views of the controversy. Dia-
betes Care 26:1932–1939, 2003
9. Amin R, Murphy N, Edge J, Ahmed ML,
Acerini CL, Dunger DB: A longitudinal
study of the effects of a gluten-free diet on
glycemic control and weight gain in sub-
jects with type 1 diabetes and celiac dis-
ease. Diabetes Care 25:1117–1122, 2002
10. Saadah OI, Zacharin M, O’Callaghan A,
Oliver MR, Catto-Smith AG: Effect of glu-
ten-free diet and adherence on growth
and diabetic control in diabetics with coe-
liac disease. Arch Dis Child 89:871–876,
2004
11. Rami B, Sumnik Z, Schober E, Waldhor T,
Battelino T, Bratanic N, Kurti K, Lebl J,
Limbert C, Madacsy L, Odink RJ, Paskova
M, Soltesz G: Screening detected celiac
disease in children with type 1 diabetes
mellitus: effect on the clinical course (a
case control study). J Pediatr Gastroenterol
Nutr 41:317–321, 2005
12. Sanchez-Albisua I, Wolf J, Neu A, Geiger
H, Wascher I, Stern M: Coeliac disease in
children with type 1 diabetes mellitus: the
effect of the gluten-free diet. Diabet Med
22:1079–1082, 2005
13. Stern M, Teuscher M, Wechmann T: Se-
rological screening for coeliac disease:
methodological standards and quality
control. Acta Paediatr Suppl 412:49–51,
1996
14. Report of Working Group of European
Society of Paediatric Gastroenterology
and Nutrition: Revised criteria for diagno-
sis of coeliac disease. Arch Dis Child 65,
909–911, 1990
15. Feighery C, Abuzakou M, Jackson J,
Clooney A, Dunne J, Willoughby R,
Whelan A: Coeliac disease serology—
EMA negative disease. In Coeliac Disease:
Proceedings of the Xth International Sympo-
sium onCoeliac Disease.Cerf-Bensussan N,
Brousse N, Caillat-Zucman S, Cellier C,
Schmitz J, Eds. Surrey, U.K., John Libbey
Eurotext, 2003, p. 183–185
16. Dube C, Rostom A, Sy R, Cranney A, Sa-
loojee N, Garritty C, Sampson M, Zhang
L, Yazdi F, Mamaladze V, Pan I, Macneil J,
Mack D, Patel D, Moher D: The preva-
lence of celiac disease in average-risk and
at-risk Western European populations: a
systematic review. Gastroenterology 128:
S57–S67, 2005
17. Basso D, Gallo N, Guariso G, Pittoni M,
Piva MG, Plebani M: Role of anti-transglu-
taminase (anti-tTG), anti-gliadin, and an-
ti-endomysium serum antibodies in
diagnosing celiac disease: a comparison of
four different commercial kits for anti-
tTG determination. J Clin Lab Anal
15:112–115, 2001
18. Barera G, Bianchi C, Calisti L, Cerutti F,
Dammacco F, Frezza E, Illeni MT, Mistura
L, Pocecco M, Prisco F, et al.: Screening of
diabetic children for coeliac disease with
antigliadin antibodies and HLA typing.
Arch Dis Child 66:491–494, 1991
19. Carlsson AK, Axelsson IE, Borulf SK,
Bredberg AC, Lindberg BA, Sjoberg KG,
Ivarsson SA: Prevalence of IgA-antien-
domysium and IgA-antigliadin autoanti-
bodies at diagnosis of insulin-dependent
diabetes mellitus in Swedish children and
adolescents. Pediatrics 103:1248–1252,
1999
20. Vitoria JC, Castano L, Rica I, Bilbao JR,
Arrieta A, Garcia M: Association of insu-
lin-dependent diabetes mellitus and ce-
liac disease: a study based on serologic
markers. J Pediatr Gastroenterol Nutr 27:
47–52, 1998
21. Sumnik Z, Kolouskova S, Cinek O, Kota-
lova R, Vavrinec J, Snajderova M: HLA-
DQA1*05-DQB1*0201 positivity pre-
disposes to coeliac disease in Czech dia-
betic children. Acta Paediatr 89:1426–
1430, 2000
22. Barera G, Bonfanti R, Viscardi M, Bazziga-
luppi E, Calori G, Meschi F, Bianchi C,
Chiumello G: Occurrence of celiac dis-
ease after onset of type 1 diabetes: a 6-year
prospective longitudinal study. Pediatrics
109:833–838, 2002
23. Fasano A: Clinical presentation of celiac
disease in the pediatric population. Gas-
troenterology 128:S68–S73, 2005
24. Westman E, Ambler GR, Royle M, Peat J,
Chan A: Children with coeliac disease and
insulin dependent diabetes mellitus—
growth, diabetes control and dietary in-
take. J Pediatr Endocrinol Metab 12:433–
442, 1999
25. Acerini CL, Ahmed ML, Ross KM, Sulli-
van PB, Bird G, Dunger DB: Coeliac dis-
ease in children and adolescents with
IDDM: clinical characteristics and re-
sponse to gluten-free diet. Diabet Med 15:
38–44, 1998
26. Kaukinen K, Salmi J, Lahtela J, Siljamaki-
Ojansuu U, Koivisto AM, Oksa H, Collin
P: No effect of gluten-free diet on the met-
abolic control of type 1 diabetes in pa-
tients with diabetes and celiac disease:
retrospective and controlled prospective
survey. Diabetes Care 22:1747–1748,
1999
27. Mohn A, Cerruto M, Lafusco D, Prisco F,
Tumini S, Stoppoloni O, Chiarelli F: Ce-
liac disease in children and adolescents
with type I diabetes: importance of hypo-
glycemia. J Pediatr Gastroenterol Nutr 32:
37–40, 2001
Celiac disease in type 1 diabetes
2456 DIABETES CARE, VOLUME 29, NUMBER 11, NOVEMBER 2006
